



Baylor Scott & White Health Plan

BSW SeniorCare HMO-POS

BSW SeniorCare PPO

2027 Medicare Part B Drugs Requiring Step Therapy

Medicare Part B Step Therapy

- Some medically administered Part B medications, like injectable drugs or biologics, may have special requirements or coverage limits, such as step therapy.
- Step therapy requires a trial of a preferred drug to treat a medical condition before covering a non-preferred drug.
- The step therapy requirement does not apply to members who have already received treatment with a non-preferred drug within the past 365 days.
- Both preferred and non-preferred drugs may still be subject to prior authorization.
- This list will be updated as additional drugs are added to the Part B drug Step Therapy program.

Drug or Drug Class	Preferred Part B Drug(s) - No Step Therapy Required	NON-Preferred Part B Drug(s) - Step Therapy Required	Effective Date
Trastuzumab	Trazimera Kanjinti Ogivri Ontruzant Herzuma	Herceptin Herceptin Hylecta	1/1/2027
Bevacizumab (oncology use)	Mvasi Zirabev	Avastin Alymsys Avzivi Vegzelma	1/1/2027
Colony Stimulating Agents (long acting)	Neulasta Udenyca	Fulphilia Fynetra Nyvepria Stimufend Ziextenzo	1/1/2027
Rituximab	Ruxience Truxima	Rituxan Rituxan Hycela Riabni	1/1/2027
Colony Stimulating Agents (short acting)	Zarxio	Neupogen Nivestym Releuko Granix	1/1/2027
Vascular Endothelial Growth Factor (VEGF) Inhibitors – For ophthalmic indications only	Avastin	Beovu Byooviz Eylea Eylea HD Lucentis Susvimo Vabysmo Pavblu	1/1/2027

Bendamustine	Belrapzo Bendeka Bendamustine Treanda	Bendamustine 505b2 formulations (Made by: Apotex and Baxter) Vivimusta	1/1/2027
Bone antiresorptive therapy (oncology use; does not apply to prostate or breast cancer)	Zoledronic acid	Xgeva Bomyntra Osenvelt Wyost Xbryk Aukelso Bilprevda Xtrenbo	1/1/2027
Taxane therapy (does not apply to pancreatic cancer, ampullary adenocarcinoma, biliary tract cancers)	Paclitaxel Docetaxel	Docetaxel 505b2 formulations (Made by: Hospira and Sandoz) Beizray Docivyx Paclitaxel Protein-Bound Abraxane Paclitaxel Protein-Bound 505b2 formulations (Made by: American Regent, Teva)	1/1/2027
Infliximab	Remicade Unbranded infliximab Renflexis	Avsola Inflectra	1/1/2027
Anti-emetics (oncology use)	Generic anti-emetics: Aprepitant Fosaprepitant Granisetron Metoclopramide Ondansetron Prochlorperazine Palonosetron	Akynzeo Cinvanti Sustol Varubi	1/1/2027
EGFR inhibitors – For colorectal cancer only	Erbix	Vectibix	1/1/2027
Irinotecan	Irinotecan conventional Camptosar	Irinotecan liposomal Onivyde	1/1/2027
Leucovorin	Fusilev Leucovorin	Khapzory	1/1/2027
PD-1 inhibitors – For metastatic nasopharyngeal cancer only	Loqtorzi	Keytruda Opdivo	1/1/2027
Pemetrexed	Pemetrexed	Axtle	1/1/2027

	Alimta Pemetrexed 505b2 formulations (Made by: Hospira, Accord, Sandoz, Teva, Bluepoint)	Pemfexy Pemrydi RTU	
Trop-2 directed antibody and topoisomerase inhibitor – for HR+/HER2- metastatic breast cancer only	Trodelyv	Datroway	1/1/2027